Abstract
Mounting evidence suggests that copper may influence the progression of Alzheimers disease by reducing clearance of the amyloid beta protein (Aß) from the brain. We propose that Aβ is cleared from the brain by tagging along with cholesterol/ApoE in traversing the BBB, with subsequent incorporation into HDL for delivery of the toxin to the liver. It is suggested that either ABC-A1 or LRP, or both are involved in Aβ transport across the BBB, as well as normal cholesterol efflux. We have previously shown that addition of only 0.12 PPM copper (one-tenth the Environmental Protection Agency Human consumption limits) to distilled water was sufficient to precipitate the accumulation of Aß in the brains of cholesterol-fed rabbits. Here we show that in a setting of elevated cholesterol levels, overproduced Aβ is cleared to the blood and can simultaneously be identified in the liver if copper ion is absent from the animals drinking water, but if trace levels copper (0.12 PPM) are added to the drinking water Aβ accumulates in the brain, while the levels in the liver are greatly reduced.
Keywords: AD-like neuropathology, amyloid-beta, liver copper, ABCA1, LRP
Current Alzheimer Research
Title: Cholesterol Metabolism and Brain Amyloidosis: Evidence for a Role of Copper in the Clearance of A β Through the Liver
Volume: 4 Issue: 2
Author(s): D. Larry Sparks
Affiliation:
Keywords: AD-like neuropathology, amyloid-beta, liver copper, ABCA1, LRP
Abstract: Mounting evidence suggests that copper may influence the progression of Alzheimers disease by reducing clearance of the amyloid beta protein (Aß) from the brain. We propose that Aβ is cleared from the brain by tagging along with cholesterol/ApoE in traversing the BBB, with subsequent incorporation into HDL for delivery of the toxin to the liver. It is suggested that either ABC-A1 or LRP, or both are involved in Aβ transport across the BBB, as well as normal cholesterol efflux. We have previously shown that addition of only 0.12 PPM copper (one-tenth the Environmental Protection Agency Human consumption limits) to distilled water was sufficient to precipitate the accumulation of Aß in the brains of cholesterol-fed rabbits. Here we show that in a setting of elevated cholesterol levels, overproduced Aβ is cleared to the blood and can simultaneously be identified in the liver if copper ion is absent from the animals drinking water, but if trace levels copper (0.12 PPM) are added to the drinking water Aβ accumulates in the brain, while the levels in the liver are greatly reduced.
Export Options
About this article
Cite this article as:
Larry Sparks D., Cholesterol Metabolism and Brain Amyloidosis: Evidence for a Role of Copper in the Clearance of A β Through the Liver, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362119
DOI https://dx.doi.org/10.2174/156720507780362119 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metacognition and Social Functioning in Schizophrenia: Evidence, Mechanisms of Influence and Treatment Implications
Current Psychiatry Reviews Schizophrenia: Redox Regulation and Volume Neurotransmission
Current Neuropharmacology Basolateral Aggregated Rat Amyloidβ(1-42) Potentiates Transmigration of Primary Rat Monocytes through a Rat Blood-Brain Barrier
Current Neurovascular Research Development of Immunopharmacotherapy Against Drugs of Abuse
Current Drug Discovery Technologies Use of Systemic Proteasome Inhibition as an Immune-Modulating Agent in Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Functional Interactions of Tau and their Relevance for Alzheimers Disease
Current Alzheimer Research Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Impacts and Concerns for vCJD in Blood Transfusion: Current Status
Current Molecular Medicine Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
Current Drug Safety Re-Balancing of Inflammation and Aβ Immunity as a Therapeutic for Alzheimers Disease-View from the Bedside
CNS & Neurological Disorders - Drug Targets Progress and Obstacles in the Application of Precision Medicine in the Management of Hepatocellular Carcinoma
Clinical Cancer Drugs Inhibition of Sulfotransferases by Xenobiotics
Current Drug Metabolism The Interaction of Zinc Oxide/Green Tea Extract Complex Nanoparticles and its Effect on Monosodium Glutamate Toxicity in Liver of Rats
Current Pharmaceutical Biotechnology Microglia and Inflammation in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Altered Mesolimbic Dopamine System in THC Dependence
Current Neuropharmacology Indole Prenyltransferases from Fungi: A New Enzyme Group with High Potential for the Production of Prenylated Indole Derivatives
Current Medicinal Chemistry Neurodegeneration and Neuroprotection in Multiple Sclerosis
Current Pharmaceutical Design Clearance of Amyloid-β Peptide Across the Choroid Plexus in Alzheimer's Disease
Current Aging Science IMGT Colliers de Perles: Standardized Sequence-Structure Representations of the IgSF and MhcSF Superfamily Domains
Current Bioinformatics The German Mouse Clinic: A Platform for Systemic Phenotype Analysis of Mouse Models
Current Pharmaceutical Biotechnology